Results 51 to 60 of about 11,087,757 (202)

Asymmetric Synthesis of Highly Functionalized Tetrahydropyran DPP‑4 Inhibitor

, 2016
A practical synthesis of a highly functionalized tetrahydropyran DPP-4 inhibitor is described. The asymmetric synthesis relies on three back-to-back Ru-catalyzed reactions.
Yoshinori Kohmura (1734763), Mahbub Alam (734001), Jeremy Scott (1734766), Michael J. Zacuto (1734769), Feng Xu (89016), David Tschaen (1734760), Andrew Gibb (667403), Jon Rosen (1734772)   +7 more
core   +1 more source

Significance of Vascular Dipeptidyl Peptidase-4 Inhibition on Vascular Protection in Zucker Diabetic Fatty Rats

Journal of Pharmacological Sciences, 2014
.: To clarify the role of dipeptidyl peptidase-4 (DPP-4) inhibition in vascular tissues, we compared the effects of the poorly tissue-penetrative DPP-4 inhibitor sitagliptin to the highly tissue-penetrative DPP-4 inhibitor linagliptin in Zucker diabetic ...
Shinji Takai, Hiroshi Sakonjo, Denan Jin
doaj   +1 more source

Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus [PDF]

Diabetes & Metabolism Journal, 2015
BackgroundPredictive factors for the efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors for lowering glycosylated hemoglobin (HbA1c) remain unclear in patients with type 2 diabetes mellitus.
Shusuke Yagi, Ken-ichi Aihara, Masashi Akaike, Daiju Fukuda, Hotimah Masdan Salim, Masayoshi Ishida, Tomomi Matsuura, Takayuki Ise, Koji Yamaguchi, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Toshio Matsumoto, Masataka Sata   +15 more
doaj   +1 more source

SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis

, 2018
To assess the efficacy and safety of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors plus a dipeptidyl peptidase‐4 (DPP‐4) inhibitor in patients with type 2 diabetes mellitus (T2DM), we performed a systematic review and meta‐analysis of 14 randomized ...
Huilin Tang, Shi, Weilong, Wang, Tiansheng, Dandan Li, Tiansheng Wang, Tang, Huilin, Weilong Shi, Li, Dandan   +7 more
core   +1 more source

DPP-4 activity affected by the presence of Myr and HP (μmol/mg/min).

, 2020
DPP-4 activity affected by the presence of Myr and HP (μmol/mg/min).
Talahalli Ravichandra Ramaprasad (8703693), Bettadahalli Sadashivaiah (8703690), Nanjaiah Lalitha (8703687), Sridevi Annapurna Singh (8703696)   +3 more
core   +1 more source

Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical Cases [PDF]

, 2016
Dipeptidyl peptidase (DPP)-4 inhibitors are a class of oral drugs used for the treatment of type 2 diabetes mellitus (T2DM). The pharmacological inhibition of DPP-4 seems to also induce adverse events related to cytokine-induced inflammation.
Mascolo, Annamaria, Sessa, Maurizio, ROSSI, Francesco, RAFANIELLO, Concetta, SPORTIELLO, Liberata, Cimmaruta, Daniela, CAPUANO, Annalisa   +6 more
core   +1 more source

Time course of the recovery of DPP-4 activity following dissociation of trelagliptin from the preformed DPP-4-inhibitor complex.

, 2016
A preformed enzyme-inhibitor complex (where [DPP-4] = 50 nmol/L and trelagliptin concentration is as shown in the plot) was diluted 50-fold into a solution containing 2 mmol/L GP-pNA substrate (approximately 17x Km).
Yoshinobu Kinugawa (3165234), Nobuhiro Nishigaki (2134261), Akiyoshi Tani (2231677), Hiroki Sano (2962497), Koji Takeuchi (469159), Charles E. Grimshaw (3165231), Andy Jennings (2235538), Hikaru Ueno (3165237), Takuo Kosaka (2231683), Lihong Shi (481066), Emiko Koumura (3165240), Ruhi Kamran (1786588)   +11 more
core   +1 more source

Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure [PDF]

, 2011
Background Progressive remodeling after myocardial infarction (MI) is a leading cause of morbidity and mortality. Recently, glucagon-like peptide (GLP)-1 was shown to have cardioprotective effects, but treatment with GLP-1 is limited by its short half ...
Rudolf A de Boer, Maxi Meissner, van Gilst Wiek H, Wiek H van Gilst, de Boer, Rudolf A., Yin Meimei, de Boer Rudolf A, Sillje, Herman H. W., van Gilst, Wiek H., Meimei Yin, Meissner Maxi, Silljé Herman HW, Yin, Meimei, Herman HW Silljé, Meissner, Maxi   +14 more
core   +2 more sources

Population Pharmacokinetic/Pharmacodynamic Analysis of the DPP-4 Inhibitor Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus

Journal of Pharmacy & Pharmaceutical Sciences, 2013
[Objectives] Linagliptin is a novel, highly selective and long acting DPP-4 inhibitor for the treatment of type 2 diabetes mellitus (T2DM). Linagliptin exhibits non-linear pharmacokinetics (PK) due to saturable binding to plasma and tissue DPP-4. The aim
Yusuke Tadayasu, Akiko Sarashina, Yasuhiro Tsuda, Shinji Tatami, Christian Friedrich, Silke Retlich, Alexander Staab, Mikihisa Takano   +7 more
doaj   +1 more source

Linagliptin, a selective DPP-4 inhibitor, inhibits DPP-4, increases incretin levels, lowers glucagon, and improves glycaemic control in patients with Type 2 diabetes. [PDF]

, 2012
Linagliptin is a xanthine-based dipeptidyl peptidase (DPP)-4 inhibitor that is now available in numerous countries worldwide for the treatment of type 2 diabetes mellitus (T2DM). The aim of this study was to evaluate further the mechanisms underlying the
Rauch, Thomas, Heise, Tim, Holst, Jens Juul, Graefe-Mody, U, Dugi, Klaus A, Rauch, T, Ring, A, Dugi, KA, Graefe-Mody, Ulrike, Deacon, Carolyn F., Heise, T, Deacon, Carolyn F, Ring, Arne, Woerle, Hans-Juergen, Woerle, H-J   +14 more
core   +1 more source